Brief: Xortx Therapeutics Inc- Announce Submission Of A Type D Meeting Request To Us FDA And A Response Setting Date For A Virtual Meeting On May 1, 2023
14/03/2023 11:17
March 14 (Reuters) - XORTX Therapeutics Inc XRTX.V :
* XORTX THERAPEUTICS INC- ANNOUNCE SUBMISSION OF A TYPE D
MEETING
REQUEST TO US FDA AND A RESPONSE SETTING DATE FOR A VIRTUAL
MEETING ON MAY 1, 2023
Source text for Eikon: ID:nGNX5ZJ1Wc
Further company coverage: XRTX.V
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on XORTX Therapeutics
See all newsBrief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
Brief: XORTX Therapeutics Announces Initiation Of Drug And Tablet Manufacturing For XRx-026 Program
Brief: Xortx Announces Termination And Postponement Of Investor Relations Program
Brief: XORTX Announces Director Resignation
Brief: Xortx Announces Us$5 Million Public Offering